Skip to main content
13 citations

Phase 3 Trials Starting the Week of September 21, 2026: Five Registered Studies Across Alzheimer's, Lung Cancer, Obesity, Myeloma, and Spinal Cord Injury

Five Phase 3 trials start the week of September 21, 2026: buntanetap in Alzheimer's, ABBV-1480 in lung cancer, zenagamtide in obesity, ramantamig in myeloma, and NVG-291 in spinal cord injury.

Five Phase 3 trials reach expected start dates in the week of September 21, 2026, according to trial registration data tracked by BioSniper. They span five companies, five therapeutic areas, and market capitalizations from under $50 million to nearly $440 billion — a cross-section of what the late-phase pipeline calendar actually looks like. This weekly digest covers each registered study in turn. Every fact below comes from the individual trial's registration record in our dataset; what a registration does not state, we mark as unknown.

Annovis Bio — Buntanetap long-term safety study in Alzheimer's disease (September 21)

Annovis Bio (ANVS) has an open-label clinical trial investigating the long-term safety of buntanetap in treating participants with Alzheimer's disease, with an expected start of September 21, 2026, recorded with "exact" date confidence and first tracked September 2, 2026. The registered design is an open-label long-term safety study; efficacy endpoints are not named in the title. Our tracker holds two earlier Annovis Phase 3 records: a 6-month and 18-month prospective, randomized study recorded February 4, 2025, and a prior open-label trial record dated January 9, 2026 with the same long-term-safety framing. Annovis's market capitalization in our snapshot is $47,718,892 — the smallest company in this digest by two orders of magnitude. Enrollment size is unknown in our data.

BioSniper AIPage evidence connected

Prepared research question

How would this research framework change the view of a company?

Run cited research

Traceable citations · Unknowns marked

AbbVie — ABBV-1480 versus pembrolizumab, both with chemotherapy, in first-line NSCLC (September 22)

AbbVie (ABBV; market capitalization $439,623,450,624 in our snapshot) has a randomized, multiregional, open-label Phase 3 of ABBV-1480 combined with chemotherapy versus pembrolizumab combined with chemotherapy as first-line treatment of locally advanced or metastatic non-small cell lung cancer, expected to start September 22, 2026, "exact" confidence, first tracked September 2, 2026. A full preview of this trial, including AbbVie's surrounding late-phase pipeline, is published separately today. The code name ABBV-1480 carries no mechanism description in our record; enrollment size and endpoints are unknown.

Novo Nordisk — Zenagamtide versus semaglutide in obesity, AMAZE 7 (September 22)

Novo Nordisk (NVO; market capitalization $197,901,565,952) has AMAZE 7 — zenagamtide subcutaneous once-weekly compared to semaglutide subcutaneous once-weekly in participants with obesity — expected to start September 22, 2026, "exact" confidence, first tracked September 2, 2026. It is a direct head-to-head against semaglutide in the obesity indication, and it runs in parallel with other zenagamtide Phase 3 records on our calendar, including an oral formulation study (AMAZE 9, expected September 1, 2026), an Asian-population study (AMAZE 13, expected January 7, 2027), and a type 2 diabetes study versus insulin glargine (expected August 24, 2026). A full preview of AMAZE 7 is published separately today. Enrollment and endpoints are unknown in our data.

GH Research — Ramantamig plus daratumumab in newly diagnosed multiple myeloma (September 22)

GH Research PLC (GHRS; market capitalization $1,891,781,376) has a Phase 3 randomized study comparing ramantamig plus daratumumab versus investigator's choice of daratumumab-based regimens (DVRd or DRd) in participants with newly diagnosed multiple myeloma for whom hematopoietic stem cell transplant is not planned as initial therapy. The expected start is September 22, 2026, "exact" confidence, first tracked September 2, 2026. The design places the experimental arm against the investigator's-choice standard in the transplant-ineligible frontline setting. Our tracker holds 50 catalyst records for GH Research; enrollment size is unknown in our data.

NervGen Pharma — NVG-291 in chronic spinal cord injury, RESTORE (September 23)

NervGen Pharma (NGEN; market capitalization $234,936,944) has the RESTORE study — a randomized, double-blind, placebo-controlled, multicenter Phase 3 investigating the efficacy and safety of NVG-291 in subjects with chronic spinal cord injury — expected to start September 23, 2026, "exact" confidence. The registration entered our dataset on September 15, 2026, making it the freshest record in this digest. RESTORE is the only placebo-controlled study among the five, and chronic spinal cord injury is the only indication here with no approved pharmacotherapy addressing the underlying condition — a fact of the therapeutic area, not a claim from our data about the drug. NervGen has no other catalyst records in our tracker yet; enrollment size is unknown.

The week at a glance

Company (ticker)DrugIndicationDesignExpected start
Annovis Bio (ANVS)BuntanetapAlzheimer's disease (long-term safety)Open-labelSeptember 21, 2026
AbbVie (ABBV)ABBV-1480 + chemoFirst-line advanced NSCLCRandomized, open-label, vs pembrolizumab + chemoSeptember 22, 2026
Novo Nordisk (NVO)ZenagamtideObesityRandomized, vs semaglutideSeptember 22, 2026
GH Research (GHRS)Ramantamig + daratumumabNewly diagnosed multiple myeloma, non-transplantRandomized, vs investigator's choiceSeptember 22, 2026
NervGen Pharma (NGEN)NVG-291Chronic spinal cord injuryRandomized, double-blind, placebo-controlledSeptember 23, 2026

All five expected-start dates carry "exact" confidence in our dataset, meaning each comes from a stated registration date rather than an estimate. None of the five has an actual-start confirmation or outcome in our data as of publication. Enrollment sizes, formal endpoint structures, and readout timing are uniformly unknown in our records — the designs above are exactly what the registrations state.

Bottom line

The week of September 21, 2026 concentrates five Phase 3 starts across Alzheimer's disease, first-line lung cancer, obesity, frontline multiple myeloma, and chronic spinal cord injury — from a $48 million micro-cap testing its lead asset to the two largest companies in our coverage window putting a next-generation candidate against their own incumbent class. We will update each event record as actual starts are confirmed and when outcomes become known.